This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://localhost/temp/predkladatel/
n15http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
skoshttp://www.w3.org/2004/02/skos/core#
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F10%3A00061165%21RIV13-MSM-14110___/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F10%3A00061165%21RIV13-MSM-14110___
rdf:type
skos:Concept n17:Vysledek
dcterms:description
We evaluate the effect of intravitreal injections of Bevacizumab (IVB) alone or combined with triamcinolone (IVT) in the first injection for treatment of refractor), diabetic macular oedema (DME). Sixty eyes of sixty patients with refractory DME were included. Half of the receive injections of IVB (1.25 mg/0.05 mL) or combined IVB and IVT (1.25 mg/0.05 mL and 2 mg/0.05 mL respectively). The primary outcome measure was change in central macular thickness (CMT). Secondary outcome measures were change in best-corrected logMAR visual acuity (BCVA) and incidence of potential adverse events. Central macular thickness was reduced significantly in both the IVB and IVB/IVT groups. At week 24, CMT change compared to the baseline was -95.7 mu m (95% CI, -172.2 to -19.26) in the IVB group and -92.1 mu m (95% CI, -154.4 to -29.7) in the IVB/IVT group. There was not a significant difference between the IVB and the IVB/IVT groups (p=0.022). We evaluate the effect of intravitreal injections of Bevacizumab (IVB) alone or combined with triamcinolone (IVT) in the first injection for treatment of refractor), diabetic macular oedema (DME). Sixty eyes of sixty patients with refractory DME were included. Half of the receive injections of IVB (1.25 mg/0.05 mL) or combined IVB and IVT (1.25 mg/0.05 mL and 2 mg/0.05 mL respectively). The primary outcome measure was change in central macular thickness (CMT). Secondary outcome measures were change in best-corrected logMAR visual acuity (BCVA) and incidence of potential adverse events. Central macular thickness was reduced significantly in both the IVB and IVB/IVT groups. At week 24, CMT change compared to the baseline was -95.7 mu m (95% CI, -172.2 to -19.26) in the IVB group and -92.1 mu m (95% CI, -154.4 to -29.7) in the IVB/IVT group. There was not a significant difference between the IVB and the IVB/IVT groups (p=0.022).
dcterms:title
Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular... Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular...
skos:prefLabel
Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular... Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular...
skos:notation
RIV/00216224:14110/10:00061165!RIV13-MSM-14110___
n4:aktivita
n16:I
n4:aktivity
I
n4:cisloPeriodika
Suppl. 2
n4:dodaniDat
n5:2013
n4:domaciTvurceVysledku
n15:7448805
n4:druhVysledku
n7:J
n4:duvernostUdaju
n8:S
n4:entitaPredkladatele
n13:predkladatel
n4:idSjednocenehoVysledku
264716
n4:idVysledku
RIV/00216224:14110/10:00061165
n4:jazykVysledku
n9:eng
n4:klicovaSlova
bevacizumab; diabetic macular oedema
n4:klicoveSlovo
n10:bevacizumab n10:diabetic%20macular%20oedema
n4:kodStatuVydavatele
HR - Chorvatská republika
n4:kontrolniKodProRIV
[FBAEE3241D6D]
n4:nazevZdroje
Collegium Antropologicum
n4:obor
n12:FP
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
2
n4:rokUplatneniVysledku
n5:2010
n4:svazekPeriodika
34
n4:tvurceVysledku
Vojnikovic, Bozo Synek, Svatopluk
n4:wos
000283961100021
s:issn
0350-6134
s:numberOfPages
5
n14:organizacniJednotka
14110